Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983665 | 0.82 | LMNA (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27711944 | 0.78 | — | — | |
| SCHEMBL8853469 | 0.76 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28264411 | 0.76 | CHRM2 (0.30) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8479451 | 0.76 | — | — | |
| SCHEMBL28995927 | 0.76 | ALOX15 (0.34) | LMNA | |
| SCHEMBL5580282 | 0.76 | CA1 (0.31) | — | |
| SCHEMBL15685824 | 0.73 | LMNA (0.30) | LMNA | |
| SCHEMBL110853 | 0.73 | LMNA (0.30) | LMNA | |
| SCHEMBL28745604 | 0.73 | CTSK (0.32) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103415525-B | Bromine domain inhibitor and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-05-18 | — | — | CN | disclosed |
| CN-104114170-A | Use of 4' -deferthionin analogues | UNIV FLORIDA | 2014-10-22 | — | — | CN | disclosed |
| CN-103648493-A | Subcutaneously infusible levodopa prodrug compositions and methods of infusion | SYNAGILE CORP | 2014-03-19 | — | — | CN | disclosed |
| CN-103201034-A | Catalysts and methods for polymer synthesis | NOVOMER INC | 2013-07-10 | — | — | CN | disclosed |
| CN-102655745-A | Use of antibacterial agents for treating epithelial-related conditions | SIGNUM BIOSCIENCES INC | 2012-09-05 | — | — | CN | disclosed |
| CN-102245021-A | Ansamycin hydroquinone compositions | INFINITY DISCOVERY INC | 2011-11-16 | — | — | CN | disclosed |
| CN-102209532-A | Method for reducing small, dense LDL particles | METABOLEX INC | 2011-10-05 | — | — | CN | disclosed |
| CN-101065148-A | Conjugated complement cascade inhibitors | DIMENSIONAL PHARM INC (US) | 2007-10-31 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CHRM2 39/4885CHRM4 129/4885CHRM5 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.